A Phase 2, Open Label, Multicentre, Sequential Dose Finding Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Multiple Doses of Polysialylated Erythropoietin [PSA-EPO; PSA-epoetin alfa; ErepoXen (registered trade name)] Administered Subcutaneously in Chronic Kidney Disease (CKD) Subjects Not on Dialysis and Not Receiving Erythropoiesis Stimulating Agents (PSA-EPO-06)
100 项与 Xenetic Biosciences (UK) Ltd. 相关的临床结果
0 项与 Xenetic Biosciences (UK) Ltd. 相关的专利（医药）
100 项与 Xenetic Biosciences (UK) Ltd. 相关的药物交易
100 项与 Xenetic Biosciences (UK) Ltd. 相关的转化医学
